Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Every word you type has to appear somewhere in the question, and the closest matches are ranked first.
15,213 questions in 2,394 reviews
current versionsNo studies 15,213 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Conjugated oral oestrogens vs transdermal 17ß‐estradiol Endometrial thickness · girls with Turner syndrome who were treated with prepubertal growth hormone Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral vs vaginal administration of oestradiol and dydrogesterone Reproductive outcomes · women with premature ovarian insufficiency (POI) awaiting oocyte donation Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Oral vs vaginal administration of oestradiol and dydrogesterone Adverse events · women with premature ovarian insufficiency (POI) awaiting oocyte donation Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Conjugated oral oestrogens vs transdermal 17ß‐estradiol Endometrial histology · girls with Turner syndrome who were treated with prepubertal growth hormone Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Conjugated oral oestrogens vs transdermal 17ß‐estradiol Uterine perfusion · girls with Turner syndrome who were treated with prepubertal growth hormone Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Conjugated oral oestrogens vs transdermal 17ß‐estradiol Reproductive outcomes · girls with Turner syndrome who were treated with prepubertal growth hormone Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Conjugated oral oestrogens vs transdermal 17ß‐estradiol Adverse events · girls with Turner syndrome who were treated with prepubertal growth hormone Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Low vs high 17ß‐oestradiol dose Endometrial thickness · young women with Turner syndrome who have completed pubertal induction Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics only Need for additional IV or oral antibiotics · children and adults with pulmonary exacerbation in CF Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Inhaled antibiotics vs IV antibiotics Time off work or school · children and adults with CF and an acute exacerbation Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Inhaled antibiotics plus IV antibiotics vs IV antibiotics only Time off work or school · children and adults with pulmonary exacerbation in CF Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intramuscular injection of bone marrow mononuclear cells (BMMNC) vs control Angiographic analysis · people with CLI who were not suitable for revascularisation and showed no improvement in response to the best standard… Local intramuscular transplantation of autologous bone marrow mononuclear cells for critical lower limb… (2022) · Cochrane | no estimate extracted | NR | No studies |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
175 mg/m2 paclitaxel vs 250 mg/m2 paclitaxel Alopecia ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Quality of Life ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Neutropenia ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
135 mg/m2 paclitaxel vs 175 mg/m2 paclitaxel Alopecia ‐ not measured · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Weekly paclitaxel vs three‐weekly paclitaxel Quality of Life ‐ not reported · women with recurrent epithelial ovarian cancer Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs placebo Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs placebo Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs placebo Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Atypical antipsychotics vs placebo Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs opioid antagonists Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Antidepressants vs mood stabilisers Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Gambling symptom severity ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Gambling expenditure ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Gambling frequency ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Time spent gambling ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Functional impairment ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Opioid antagonists vs mood stabilisers Responder status ‐ not measured · treatment of disordered and problem gambling Pharmacological interventions for the treatment of disordered and problem gambling (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Recurrence during · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Long‐term complications during · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Long‐term emergency surgery during · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ All‐cause mortality · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Primary ‐ Short‐term complications (abscess, perforation, obstruction or fistula) within 30 days · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Primary ‐ Short‐term emergency surgery within 30 days · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Recurrence during · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Long‐term emergency surgery during · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ All cause mortality · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Secondary ‐ Adverse events · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Primary ‐ Short‐term complications (abscess, perforation, obstruction or fistula) within 30 days · Patients with acute uncomplicated diverticulitis Antibiotics for uncomplicated diverticulitis (2022) · Cochrane | no estimate extracted | NR | No studies |
Supportive and counselling interventions vs treatment Depression remission post‐treatment · depression and anxiety for people with dementia Psychological treatments for depression and anxiety in dementia and mild cognitive impairment (2022) · Cochrane | no estimate extracted | NR | No studies |
Brief admission to psychiatric hospital by self‐referral plus treatment as usual vs treatment Quality of life · adults meeting 3 or more diagnostic criteria for borderline personality disorder Crisis interventions for adults with borderline personality disorder (2022) · Cochrane | no estimate extracted | NR | No studies |